This is a standard annual meeting with no contentious issues. Monitor the company's next 10-Q filing for any changes in strategy or financial performance.
Price Chart
Executive Summary
Verrica Pharmaceuticals is holding its 2026 Annual Meeting to vote on four key proposals: the election of two directors (Paul B. Manning and Lawrence Eichenfield), approval of executive compensation, ratification of KPMG LLP as the independent auditor, and approval of the Amended and Restated 2018 Equity Incentive Plan. This is a routine management-led proxy statement with no activist opposition.
Key Financial Metrics
Key Facts
- The filing is a definitive proxy statement (DEFA14A) for Verrica's 2026 Annual Meeting.
- The meeting will be held on June 5, 2026, at the company's headquarters in West Chester, PA.
- Four proposals are on the ballot: director election, executive compensation approval, auditor ratification, and an equity incentive plan.
- The board recommends voting 'For' on all proposals.
- The filing is routine and management-led, with no indication of shareholder dissent or activism.
Financial Impact
The filing has no direct financial impact. It is a procedural document for a routine shareholder vote.
Risk Factors
- The approval of the equity incentive plan could lead to future share dilution.
- Routine governance filings can sometimes mask underlying issues, so continued monitoring is advised.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-164025 |
| Document: 0001193125-26-164025-index-headers.html | 0001193125-26-164025 |
| Document: 0001193125-26-164025-index.html | 0001193125-26-164025 |
| Document: 0001193125-26-164025.txt | 0001193125-26-164025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Press Release | $4.95 $4.18 | ▼ −15.56% | ▼ −17.68% | $3.47 (−29.90%) |
Jun 9, 2026 20w ago | 8-K | $5.75 $6.53 | ▲ +13.57% | ▲ +9.94% | $3.47 (−39.65%) |
May 12, 2026 24w ago | 8-K | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.47 (−52.92%) |
May 12, 2026 24w ago | Press Release | $7.37 $6.03 | ▼ −18.25% | ▼ −17.64% | $3.47 (−52.92%) |
Apr 20, 2026 27w ago | DEFA14A | $6.32 $5.87 | ▼ −7.12% | ▼ −12.04% | $3.47 (−45.09%) |
Mar 11, 2026 32w ago | Press Release | $6.26 $5.83 | ▼ −6.87% | ▼ −7.39% | $3.47 (−44.57%) |
Mar 4, 2026 33w ago | Court Ruling | $5.20 $5.47 | ▼ −5.19% | ▼ −8.67% | $3.47 (+33.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers